Immutep Ltd
IMMP2.620USD
0.0000.00%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
3.83BValor de mercado
PerdaP/L TTM
Mais detalhes de Immutep Ltd Empresa
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Informações de Immutep Ltd
Código da empresaIMMP
Nome da EmpresaImmutep Ltd
Data de listagemJun 23, 1988
CEOVoigt (Marc)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 23
EndereçoLevel 32, Suite 32.07 Australia Square
CidadeSYDNEY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal2000
Telefone61283157003
Sitehttps://www.immutep.com/
Código da empresaIMMP
Data de listagemJun 23, 1988
CEOVoigt (Marc)
Executivos da empresa Immutep Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
17.06K
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.00
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
--
--
Dr. Russell John Howard, Ph.D.
Dr. Russell John Howard, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Peter A. (Pete) Meyers
Mr. Peter A. (Pete) Meyers
Independent Non-Executive Deputy Chairman of the Board
Independent Non-Executive Deputy Chairman of the Board
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Company Secretary
Company Secretary
--
--
Ms. Lis (Elisabeth) Boyce
Ms. Lis (Elisabeth) Boyce
Non-Executive Director
Non-Executive Director
--
--
Dr. Stephan Winckels
Dr. Stephan Winckels
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Christian Mueller
Mr. Christian Mueller
Chief Development Officer
Chief Development Officer
--
--
Ms. Eleanor Pearson
Ms. Eleanor Pearson
Investors Relation
Investors Relation
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
17.06K
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.00
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
--
--
Dr. Russell John Howard, Ph.D.
Dr. Russell John Howard, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Peter A. (Pete) Meyers
Mr. Peter A. (Pete) Meyers
Independent Non-Executive Deputy Chairman of the Board
Independent Non-Executive Deputy Chairman of the Board
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Company Secretary
Company Secretary
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 1 de fev
Atualizado em: dom, 1 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Pengana Capital Group Limited
0.66%
BlackRock Institutional Trust Company, N.A.
0.39%
Meridian Wealth Management, LLC
0.31%
Sender Company & Partners, Inc
0.15%
Morgan Stanley & Co. LLC
0.11%
Outro
98.38%
Investidores
Investidores
Proporção
Pengana Capital Group Limited
0.66%
BlackRock Institutional Trust Company, N.A.
0.39%
Meridian Wealth Management, LLC
0.31%
Sender Company & Partners, Inc
0.15%
Morgan Stanley & Co. LLC
0.11%
Outro
98.38%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
0.96%
Investment Advisor
0.92%
Research Firm
0.19%
Hedge Fund
0.12%
Venture Capital
0.02%
Individual Investor
0.01%
Outro
97.78%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
56
3.30M
2.24%
-356.89K
2025Q3
54
2.86M
1.94%
-666.36K
2025Q2
57
2.80M
1.91%
-1.07M
2025Q1
57
2.80M
1.92%
-1.15M
2024Q4
60
6.95M
4.78%
-4.23M
2024Q3
60
9.14M
6.30%
-2.51M
2024Q2
63
9.65M
6.65%
+2.67M
2024Q1
67
3.50M
2.94%
-1.44M
2023Q4
66
3.16M
2.65%
-1.77M
2023Q3
71
3.00M
2.53%
-4.97M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Pengana Capital Group Limited
970.61K
0.66%
--
--
May 31, 2025
BlackRock Institutional Trust Company, N.A.
580.44K
0.39%
-19.49K
-3.25%
Sep 30, 2025
Meridian Wealth Management, LLC
420.90K
0.29%
+48.20K
+12.93%
Sep 30, 2025
Sender Company & Partners, Inc
215.86K
0.15%
+93.11K
+75.85%
Sep 30, 2025
Morgan Stanley & Co. LLC
160.47K
0.11%
+47.50K
+42.05%
Sep 30, 2025
AllianceBernstein L.P.
140.05K
0.1%
+60.49K
+76.04%
Jun 30, 2024
Susquehanna International Group, LLP
95.25K
0.06%
+36.94K
+63.36%
Sep 30, 2025
Verition Fund Management LLC
75.00K
0.05%
+31.00K
+70.45%
Sep 30, 2025
UBS Financial Services, Inc.
25.09K
0.02%
-39.75K
-61.30%
Sep 30, 2025
Jane Street Capital, L.L.C.
55.46K
0.04%
+55.46K
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Biotechnology ETF
0.02%
ActivePassive International Equity ETF
0%
DFA Dimensional International Small Cap ETF
0%
iShares Biotechnology ETF
Proporção0.02%
ActivePassive International Equity ETF
Proporção0%
DFA Dimensional International Small Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
